TABLE 1.
Recently Completed and Ongoing Trials Combining MET Inhibitors With Immune Checkpoint Inhibitors
| Trial | Arms | No. of Patients With Papillary RCC | ORR | PFS | OS |
|---|---|---|---|---|---|
| NCT03635892 | Nivolumab + cabozantinib (ClinicalTrials.gov identifier: NCT03635892) | 32 | 47% | 12.5 monthsa | 28.0 monthsa |
| COSMIC-021 (ClinicalTrials.gov identifier: NCT03170960) | Atezolizumab + cabozantinib | 15 | 47% | 9.5 monthsa | Not reported |
| CALYPSO (ClinicalTrials.gov identifier: NCT02819596) | Durvalumab + savolitinib | 41 | 27% | 4.9 months | 14.1 months |
| PAPMET2 (ClinicalTrials.gov identifier: NCT05411081) | Atezolizumab + cabozantinib v cabozantinib | 200 (expected) | – | – | – |
| SAMETA (ClinicalTrials.gov identifier: NCT05043090) | Durvalumab + savolitinib v durvalumab v sunitinib | 220 (expected) | – | – | – |
| STELLAR-304 (ClinicalTrials.gov identifier: NCT05678673) | Nivolumab + zanzalintinib v sunitinib | 291a | – | – | – |
Abbreviations: ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma.
a
Includes full non–clear cell RCC cohort.